Citius Pharma up on plans to resubmit marketing application for cancer drug

Citius Pharmaceuticals

08/09/2023 14:38

** Citius Pharmaceuticals'  CTXR.O  shares rise 3.5% to 90
cents 
    ** Co says it plans to resubmit the marketing application
for its blood cancer drug Lymphir after receiving additional
guidance from the U.S. FDA
    ** Says FDA has not requested any additional clinical
efficacy or safety trials for the resubmission
    ** The FDA had earlier declined to approve co's drug on July
28, 2023 
    ** Up to last close, shares were up 10.8% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))